Abstract: A virtual medical instrument (VMI) system comprises data storage for storing input diagnostic test protocols for two or more of EEG, EKG, EMG/NCV, PFT, CMG, EP, ENG, visual acuity, visual field, limb dynometric and audiogram testing. The VMI system includes a universal interface having a number of electrical contacts and sets of electrical conduits associated with the different stored diagnostic test protocols. A selector enables a system user to select any one of the stored diagnostic test protocols for conducting on a patient. The system is constructed to enable the selected diagnostic test protocol to be performed on a patient after the corresponding set of electrical conduits are connected to the universal interface contacts and to the patient. Further included is an electrical signal generator connected to the universal interface for providing electrical signals to the patent if such electric signals are required by the selected test protocol.

Abstract: A modular wristwatch assembly comprises a bezel having a transparent watch crystal mounted therein, first and second pairs of watch band lugs joined to opposite exterior side edge regions of the bezel, a rigid watch back member, and a rigid, annular watch movement retaining member disposed between the bezel and the back member. Included in the assembly are a watch movement, having a watch face and hands for indicating the time, installed in the watch movement retaining member and having operating controls extending outwardly therethrough. There is further included a decorative ring installed between an under surface of the bezel and an upper surface of the watch face, the ring being around peripheral edge regions of the face so as not to interfere with the time indicating means and being visible through said watch crystal. Screws are used for detachablably attach the bezel and the watch back member together with the watch movement retaining member and watch movement held therebetween.

Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having potassium channel blocking activity. Examples of potassium channel blockers utilized in the pharmaceutical composition and method of treatment are quinine, tremogenic indole alkaloids, such as Penitrem A and paspalicine, and insect toxins such as charybdotoxin and iberiotoxin.

Abstract: An electronic switched-output controller apparatus comprises a plurality of relays for providing a plurality of controlled switched outputs, the relays being selected from the group consisting of power relays, signal switching relays, dry contact closing relays and combinations thereof, each of the relays having a corresponding relay operating coil. A power section is configured for receiving AC line power and for providing internal operating DC voltage and is connected for providing line AC power to any power relays and thereby to corresponding outputs when the corresponding power relay coils are actuated, and for providing DC voltage to any signal switching relays and thereby to corresponding outputs when the corresponding switching signal relay coils are activated.

Abstract: A portable water shower apparatus comprises a pressure vessel capable of withstanding an internal pressure of at least about 50 psig. The vessel, which may be sized to hold from about 1 to about 21/4 gallons of water, is formed having an liquid filling and emptying opening and a combination handle and manual pressurizing pump which seals the opening against pressure loss when the vessel is pressurized. The vessel has a pressurized fluid outlet fitting and the apparatus includes an elongate liquid discharge conduit which is detachably attached to the vessel outlet fitting and which has a manually-operated shower head attached to the distal end of the hose for controlling the flow of pressurized liquid from the vessel. A conventional valve stem is provided for the vessel enabling the vessel to be pressurized by use of a CO.sub.2 device available in bicycle shops. A pressure relief valve is mounted to the vessel to prevent over-pressurizing the vessel.

Abstract: An orthodontic palate expander apparatus comprises an expansion screw assembly having first and second side plates with a threaded member connected between the plates so that its rotation in a first rotational direction about its longitudinal axis causes the plates to move away from one another in a palate expanding manner and rotation of it in the opposite direction causes the side plates to move toward one another for adjustment of the apparatus. A first gear is fixed to central regions of the threaded member and a second gear is mounted in driving relationship therewith. Manual rotation of the second gear thus causes rotation of the threaded member to thereby move the plates toward or away from each other according to the direction in which the second gear is rotated. The second gear is oriented so that with the apparatus installed in a patient's palate portions of the second gear are accessible through the patient's open mouth for turning the gear, for example, with an Allen wrench or screwdriver.

Abstract: An orthotic device is disclosed which is useful for extending the range of angular movement between adjacent first and second skeletal body parts which are and have been drawn to and involuntarily held in an immobile angular position relative to one another by contraction of muscles and connective tissue due to immobility. The orthotic device comprises first and second orthotic device portions which are interconnected for permitting pivotal angular motion therebetween for establishing an initial angle therebetween.

Abstract: The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I: ##STR1## wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched segments indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration, dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R.sup.1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of --OR.sup.1 and --N(R.sup.1).sub.2, Y is .dbd.O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.

Abstract: The invention relates to 7-?5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxycyclopentyl(enyl)! heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.

Abstract: A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering a retinoid, such as an RAR-selective retinoid, e.g.

Abstract: A virtual medical instrument (VMI) system comprises data storage for storing input diagnostic test protocols for two or more of EEG, EKG, EMG/NCV, PFT, CMG, EP, ENG, visual acuity, visual field, limb dynometric and audiogram testing. The VMI system includes a universal interface having a number of electrical contacts and sets of electrical conduits associated with the different stored diagnostic test protocols. A selector enables a system user to select any one of the stored diagnostic test protocols for conducting on a patient. The system is constructed to enable the selected diagnostic test protocol to be performed on a patient after the corresponding set of electrical conduits are connected to the universal interface contacts and to the patient. Further included is an electrical signal generator connected to the universal interface for providing electrical signals to the patent if such electric signals are required by the selected test protocol.

Abstract: The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are encompassed by the following structure formula I: ##STR1## wherein wavy line attachments indicate either the alpha (a) or beta (b) configuration; hatched lines indicate a configuration, solid triangles are used to indicate b configuration, dashed bonds represent a double bond, or a single bond; n is 0, or an integer of from 1 to 3; X is NH.sub.2 or OR; R is hydrogen, R.sub.4 or a --(CO)R.sub.4 group; R.sub.1, R.sub.2, and R.sub.3 independently are hydroxyl, or --O(CO)R.sub.5 groups, wherein R.sub.4 and R.sub.5 independently stand for saturated or unsaturated acyclic hydrocarbon having from 1 to 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.6 where m is 0-10 and R.sub.6 is an aliphatic, aromatic or heteroaromatic ring, R.sub.7 and R.sub.8 together are .dbd.

Abstract: The present invention provides a method of effecting vasodilation, comprising:administering to a warm blooded animal in need of such treatment, an effective amount of a (1,5-inter) aryl prostaglandin derivative represented by the Formula I ##STR1## wherein n is 0 or an integer of from 1 to 6, R is selected from the group of radicals represented by the formulae:CO.sub.2 R', CONR'.sub.2, CH.sub.2 OR' and SO.sub.2 NR'.sub.2 'wherein R' is hydrogen or a lower alkyl radical having from one to six carbon atoms; R" is hydrogen or an acyl radical having the formula (CO)R'" wherein R'" is a saturated or unsaturated acyclic hydrocarbon radical having from 1 to about 10 carbon atoms, or --(CH.sub.2).sub.m R"" wherein m is 0 or an integer of from 1 to 6 and R"" is an aliphatic ring having from 3 to 7 carbon atoms or an aryl group, e.g. phenyl, or a heteroaryl group, e.g.

Abstract: The present invention provides to cyclopentane heptanoic acid, 2 heteroaryl alkyl or alkenyl derivatives which may be substituted in the 1-position with hydroxyl, alkyloxy, amino and amido groups, e.g. 1-OH cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives. In particular, these derivatives are 7-?5-hydroxy-2-(heteroatom-substituted hydroxyhydrocarbyl)-3-hydroxycyclopentyl!heptanoic or heptenoic acids and amine, amide, ether, ester and alchohol derivatives of said acids wherein one or more of said hydroxy groups are replaced with an ether group. These compounds are potent ocular hypotensive and are particularly suited for the management of glaucoma.

Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering a therapeutically effective amount of a thromboxane ligand which is a compound of formula I, ##STR1## wherein Y is (CH.sub.2).sub.x ; Z is selected from the group consisting of ##STR2## x is an integer of 1 or 2; R.sub.2 is hydrogen or an alkyl radical of from 1 to 4 carbons, A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted or said alkylene or alkenylene may have one or more enchained oxo or imino radicals; B is a methyl radical, a cycloalkyl radical, or an aryl radical, or substituted derivatives of said methyl, cycloalkyl or aryl radicals and X is selected from the group consisting of nitro, cyano, --COOR, --CH.sub.2 OR.sub.1, --C(O)N(R.sub.1).sub.2, --CH.sub.2 N(R.sub.1).sub.2 --CH.dbd.N--OH and --CH.

Abstract: A polymeric material incorporating a polyvalent cation chelating agent in an amount effective to inhibit the growth of an ocular pathogen, particularly a protozoan, can be used to produce eye care products such as contact lens cases and containers for containing eye care solutions and contact lenses.

Abstract: Disclosed are pharmaceutical compositions comprising dipivefrin and levobunolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: A fluid flow rate control device, especially adapted for controlling the flow of IV fluid to a patient, comprises a first vented fluid chamber having an upper fluid inlet end with a hollow spike which enables fluid connection with a conventional fluid container. A free floating float valve in the first chamber blocks the flow of fluid into the first chamber from the fluid container according to whether or not the fluid level in the first chamber is at a preestablished fluid level, thereby providing a constant pressure head regardless of fluid level in the fluid container. A lower end of the first chamber is connected, through a flow regulator, such as a screw-type valve, to an upper inlet end of a second, vented, drip chamber, the lower end of which is adapted for connection to a discharge tube, such as an IV tube.

Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having chloride channel blocking activity. Examples of chloride channel blockers utilized in the pharmaceutical composition and method of treatment are: ##STR1## wherein R is hydrogen or a pharmaceutically-acceptable cation, e.g. an alkali or alkaline earth metal, or a quaternary amine; or R represents a ester-forming moiety, e.g. a lower alkyl radical, having up to six carbon atoms, that may be derived from a lower alkanol.